Total hip arthroplasty in HIV-infected patients: a retrospective, controlled study
Article first published online: 15 APR 2012
© 2012 British HIV Association
Volume 13, Issue 10, pages 623–629, November 2012
How to Cite
Tornero, E., García, S., Larrousse, M., Gallart, X., Bori, G., Riba, J., Rios, J., Gatell, J. and Martinez, E. (2012), Total hip arthroplasty in HIV-infected patients: a retrospective, controlled study. HIV Medicine, 13: 623–629. doi: 10.1111/j.1468-1293.2012.01017.x
- Issue published online: 11 OCT 2012
- Article first published online: 15 APR 2012
- Manuscript Accepted: 27 FEB 2012
- femoral necrosis;
- hip arthroplasty;
Although HIV-infected patients are at greater risk of presenting with ischaemic necrosis of the femoral head, there have been concerns about whether total hip arthroplasty (THA) may have worse outcomes than expected.
From the Orthopedic and Trauma Surgery database we identified all patients who had undergone THA because of ischaemic necrosis of the femoral head from January 2001 until March 2010. Patient's diagnosis of HIV infection was confirmed at the time of arthroplasty by cross-matching with the HIV unit database. For every THA in HIV-infected patients, two THAs in patients not known to be HIV-infected, with the same diagnosis of ischaemic necrosis of the femoral head and having undergone surgery over the same period, were randomly selected. THAs were compared in HIV- and non-HIV-infected patients for surgical procedure, in-patient stay and long-term prognosis.
There were 18 THAs in 13 HIV-infected patients and 36 THAs in 27 non-HIV-infected patients. No significant differences were observed in the mean time spent in surgery (106 vs. 109 minutes, respectively; P = 0.66), the need for red cell transfusion (1 vs. 4, respectively; P = 0.48) or the mean duration of hospitalization (7.8 vs. 9.4 days, respectively; P = 0.48). The two groups showed similar postoperative functional results, which were maintained until the end of the follow-up period (median 3.3 years in the HIV-positive group and 5.8 years in the HIV-negative group).
Our study suggests that the outcome of THA in HIV-positive patients is not worse than that of HIV-negative patients, although future research on larger numbers of patients is required to confirm this.